Pig tissue factor pathway inhibitor α fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart

Chang Yong Choi; Yeon Hui Kim; Joonbeom Bae; Suk Jun Lee; Hyun Kyung Kim; Chung Gyu Park; Taehoon Chun

doi:10.1007/s10529-017-2405-3

Pig tissue factor pathway inhibitor α fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart

Chang Yong Choi, Yeon Hui Kim, Joonbeom Bae, Suk Jun Lee, Hyun Kyung Kim, Chung Gyu Park, Taehoon Chun

Department of Biotechnology

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Objective: To determine the efficacy of soluble pig tissue factor pathway inhibitor fusion immunoglobulin (TFPI-Ig) in blocking pig to human xenogeneic blood coagulation. Results: To generate pig TFPI-Ig or human TFPI-Ig, expression vector containing cDNA encoding pig TFPIα or human TFPIα combined with human constant Ig heavy chain region was cloned and introduced into CHO cells. After purification of pig TFPI-Ig and human TFPI-Ig, the inhibition of each recombinant protein on pig tissue factor (TF)-mediated blood coagulation was examined in human plasma. Compared to human TFPI-Ig, pig TFPI-Ig inhibited pig TF activity and thrombin generation in human plasma more efficiently at certain concentrations. Conclusions: Pig TFPI-Ig will be be useful as a therapeutic protein to treat pig to human xenogeneic blood coagulation.

Original language	English
Pages (from-to)	1631-1638
Number of pages	8
Journal	Biotechnology letters
Volume	39
Issue number	11
DOIs	https://doi.org/10.1007/s10529-017-2405-3
Publication status	Published - 2017 Nov 1

Bibliographical note

Funding Information:
This work was supported by a grant (Grant Number: HI13C0954) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &Welfare, Republic of Korea.

Publisher Copyright:
© 2017, Springer Science+Business Media B.V.

Keywords

Blood coagulation
Recombinant protein
Tissue factor
Tissue factor pathway inhibitor
Xenotransplantation

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology

Access to Document

10.1007/s10529-017-2405-3

Cite this

@article{881641bbfa0f4ad59f6565f84d756c22,

title = "Pig tissue factor pathway inhibitor α fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart",

abstract = "Objective: To determine the efficacy of soluble pig tissue factor pathway inhibitor fusion immunoglobulin (TFPI-Ig) in blocking pig to human xenogeneic blood coagulation. Results: To generate pig TFPI-Ig or human TFPI-Ig, expression vector containing cDNA encoding pig TFPIα or human TFPIα combined with human constant Ig heavy chain region was cloned and introduced into CHO cells. After purification of pig TFPI-Ig and human TFPI-Ig, the inhibition of each recombinant protein on pig tissue factor (TF)-mediated blood coagulation was examined in human plasma. Compared to human TFPI-Ig, pig TFPI-Ig inhibited pig TF activity and thrombin generation in human plasma more efficiently at certain concentrations. Conclusions: Pig TFPI-Ig will be be useful as a therapeutic protein to treat pig to human xenogeneic blood coagulation.",

keywords = "Blood coagulation, Recombinant protein, Tissue factor, Tissue factor pathway inhibitor, Xenotransplantation",

author = "Choi, {Chang Yong} and Kim, {Yeon Hui} and Joonbeom Bae and Lee, {Suk Jun} and Kim, {Hyun Kyung} and Park, {Chung Gyu} and Taehoon Chun",

note = "Funding Information: This work was supported by a grant (Grant Number: HI13C0954) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &Welfare, Republic of Korea. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media B.V.",

year = "2017",

month = nov,

day = "1",

doi = "10.1007/s10529-017-2405-3",

language = "English",

volume = "39",

pages = "1631--1638",

journal = "Biotechnology letters",

issn = "0141-5492",

publisher = "Springer Netherlands",

number = "11",

}

TY - JOUR

T1 - Pig tissue factor pathway inhibitor α fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart

AU - Choi, Chang Yong

AU - Kim, Yeon Hui

AU - Bae, Joonbeom

AU - Lee, Suk Jun

AU - Kim, Hyun Kyung

AU - Park, Chung Gyu

AU - Chun, Taehoon

N1 - Funding Information: This work was supported by a grant (Grant Number: HI13C0954) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &Welfare, Republic of Korea. Publisher Copyright: © 2017, Springer Science+Business Media B.V.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objective: To determine the efficacy of soluble pig tissue factor pathway inhibitor fusion immunoglobulin (TFPI-Ig) in blocking pig to human xenogeneic blood coagulation. Results: To generate pig TFPI-Ig or human TFPI-Ig, expression vector containing cDNA encoding pig TFPIα or human TFPIα combined with human constant Ig heavy chain region was cloned and introduced into CHO cells. After purification of pig TFPI-Ig and human TFPI-Ig, the inhibition of each recombinant protein on pig tissue factor (TF)-mediated blood coagulation was examined in human plasma. Compared to human TFPI-Ig, pig TFPI-Ig inhibited pig TF activity and thrombin generation in human plasma more efficiently at certain concentrations. Conclusions: Pig TFPI-Ig will be be useful as a therapeutic protein to treat pig to human xenogeneic blood coagulation.

AB - Objective: To determine the efficacy of soluble pig tissue factor pathway inhibitor fusion immunoglobulin (TFPI-Ig) in blocking pig to human xenogeneic blood coagulation. Results: To generate pig TFPI-Ig or human TFPI-Ig, expression vector containing cDNA encoding pig TFPIα or human TFPIα combined with human constant Ig heavy chain region was cloned and introduced into CHO cells. After purification of pig TFPI-Ig and human TFPI-Ig, the inhibition of each recombinant protein on pig tissue factor (TF)-mediated blood coagulation was examined in human plasma. Compared to human TFPI-Ig, pig TFPI-Ig inhibited pig TF activity and thrombin generation in human plasma more efficiently at certain concentrations. Conclusions: Pig TFPI-Ig will be be useful as a therapeutic protein to treat pig to human xenogeneic blood coagulation.

KW - Blood coagulation

KW - Recombinant protein

KW - Tissue factor

KW - Tissue factor pathway inhibitor

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=85026916923&partnerID=8YFLogxK

U2 - 10.1007/s10529-017-2405-3

DO - 10.1007/s10529-017-2405-3

M3 - Article

C2 - 28748351

AN - SCOPUS:85026916923

SN - 0141-5492

VL - 39

SP - 1631

EP - 1638

JO - Biotechnology letters

JF - Biotechnology letters

IS - 11

ER -

Pig tissue factor pathway inhibitor α fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this